In Massachusetts, Xenetic Biosciences, Inc. has a new Chief Scientific Officer, Curtis A. Lockshin. Lockshin’s experience with research and development in the biopharmaceutical industry and his various biomaterials, therapeutics and biosensors inventions and patents will come in handy in his new role at Xenetic, a biopharmaceutical company. Lockshin was formerly a CEO, or served in other executive roles, at SciVac Therapuetics, VBI Vaccines, Guardum Pharmaceuticals, and OPKO Health. Lockshin will help Xenetic with their focus on next-gen biologic drugs and oncology therapeutics. Scott Maguire, Chief Executive Officer of Xenetic said in their press release “With our second important executive level appointment since our Nasdaq listing, Xenetic now has a structure to deliver on what we believe will be a transformational 2017.”
Latest article
Tums battles heartburn and climate change with new biobased packaging
In Missouri, the multinational behind Tums has partnered with Pretium Packaging and LyondellBasell to create a biobased bottle for the antacid.
At the recent...
Vegan Society certifies interior of Mercedes-Benz GLC
In Germany, Mercedes-Benz’s GLC model has become the first car to have an interior certified by the Vegan Society. Vegan materials were used throughout the...
Wooden Bentley replica finds a home in Boca Raton
In Boca Raton, the Auto Sport Florida group has acquired a wooden replica of the original Bentley Continental GT, with sculpted wood being used...